ESC 365 - Long-term evolution of estimated glomerular filtration rate in heart failure

Back

ESC Premium Access

Long-term evolution of estimated glomerular filtration rate in heart failure

Session: Diabetes and kidney disease in heart failure: how should we treat the terrible triplets?

Topic: Comorbidities

Speaker: Miss C. Escabia Riera (Badalona, ES)

Event: ESC Congress 2021 - The Digital Experience

Presentation

About the speaker

Miss Claudia Escabia Riera

Germans Trias and Pujol Hospital, Badalona (Spain)

0 follower

4 more presentations in this session

Clinical outcomes and death associated with cardiorenal syndromes. A comprehensive nationwide cohort study

Speaker: Professor L. Fauchier (Tours, FR)

Influence of diabetes, heart failure, and NT-proBNP on cardiovascular outcomes in patients with atrial fibrillation - Insights from a cohort study of 7,412 patients with extended follow-up

Speaker: Doctor F. Hofer (Vienna, AT)

Outcomes of diabetic patients with end-stage heart failure listed for heart transplantation: a propensity-matched analysis

Speaker: Assistant Professor A. Briasoulis (Iowa City, US)

Clinical course and related costs of patients with diabetes and heart failure and/or chronic kidney disease, drawn from a sample of more than 7 million people

Speaker: Professor A. Maggioni (Florence, IT)

Access the full session

Diabetes and kidney disease in heart failure: how should we treat the terrible triplets?

Speakers: Miss C. Escabia Riera, Professor L. Fauchier, Doctor F. Hofer, Assistant Professor A. Briasoulis, Professor A. Maggioni

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Hemoglobin, anemia, and clinical outcomes in vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA)

27 August 2021

ESC Premium Access

Blood pressure control in the general and high risk populations, longitudinal trends.

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

Long-term evolution of estimated glomerular filtration rate in heart failure

About the speaker

Miss Claudia Escabia Riera

4 more presentations in this session

Clinical outcomes and death associated with cardiorenal syndromes. A comprehensive nationwide cohort study

Influence of diabetes, heart failure, and NT-proBNP on cardiovascular outcomes in patients with atrial fibrillation - Insights from a cohort study of 7,412 patients with extended follow-up

Outcomes of diabetic patients with end-stage heart failure listed for heart transplantation: a propensity-matched analysis

Clinical course and related costs of patients with diabetes and heart failure and/or chronic kidney disease, drawn from a sample of more than 7 million people

Access the full session

Diabetes and kidney disease in heart failure: how should we treat the terrible triplets?

About the event

ESC Congress 2021 - The Digital Experience

Related content

Hemoglobin, anemia, and clinical outcomes in vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA)

Blood pressure control in the general and high risk populations, longitudinal trends.

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

This platform is supported by